Goldman Sachs Maintains Buy on Praxis Precision Medicine, Raises Price Target to $575
Goldman Sachs analyst Kevin Strang maintains Praxis Precision Medicine (NASDAQ:PRAX) with a Buy and raises the price target from $470 to $575.
Stocks · News reference
Praxis Precision Medicine Q2 EPS $(2.87) Beats $(3.65) Estimate
Praxis Precision Medicine (NASDAQ:PRAX) reported quarterly losses of $(2.87) per share which beat the analyst consensus estimate of $(3.65) by 21.37 percent. This is a 13.29 percent increase over losses of $(3.31) per
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
RBC Capital Maintains Outperform on Praxis Precision Medicine, Raises Price Target to $462
RBC Capital analyst Leonid Timashev maintains Praxis Precision Medicine (NASDAQ:PRAX) with a Outperform and raises the price target from $449 to $462.
Wells Fargo Maintains Equal-Weight on Praxis Precision Medicine, Raises Price Target to $362
Wells Fargo analyst Benjamin Burnett maintains Praxis Precision Medicine (NASDAQ:PRAX) with a Equal-Weight and raises the price target from $323 to $362.
Needham Maintains Buy on Praxis Precision Medicine, Raises Price Target to $582
Needham analyst Ami Fadia maintains Praxis Precision Medicine (NASDAQ:PRAX) with a Buy and raises the price target from $575 to $582.